help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walden, C. C.
Right arrow Articles by Hegele, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walden, C. C.
Right arrow Articles by Hegele, R. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Journal of Clinical Endocrinology & Metabolism, Vol 78, 699-704, Copyright © 1994 by Endocrine Society

ARTICLES

Detection of a new apolipoprotein-E mutation in type III hyperlipidemia using deoxyribonucleic acid restriction isotyping

CC Walden, MW Huff, LA Leiter, PW Connelly and RA Hegele
Department of Medicine, St. Michael's Hospital, University of Toronto, Ontario, Canada.

While determining the apolipoprotein-E (apo-E) genotype of 22 patients with type III hyperlipidemia (HLP III) by restriction isotyping, we identified a new mutant form of apo-E by its unusual DNA restriction fragment length polymorphism pattern. DNA sequence analysis of a polymerase chain reaction-amplified portion of the proband's apo-E gene revealed the substitution of cysteine (TGC) for arginine (CGC) at position 136 in the mutant allele (designated R136C). Lipoproteins containing this mutant protein bound defectively to macrophages in vitro, confirming the contribution of R136C to the expression of HLP III in the proband. The proband's two siblings carried the mutant allele and were also heterozygous for E2. Each also had dysbetalipoproteinemia (indicated by the presence of beta-very low density lipoprotein), but neither was hyperlipidemic, attesting to the importance of other factors for the full expression of HLP III. The mutant allele appears to contribute to the inheritance of HLP III in a recessive fashion. Restriction isotyping facilitates the diagnosis of subjects with HLP III, aids in the identification of affected individuals through family screening, and can contribute to the discovery of new mutations that help explain the pathogenesis of HLP III.


This article has been cited by other articles:


Home page
 J. Lipid Res.Home page
M. K. Bolla, N. Wood, and S. E. Humphries
Rapid determination of apolipoprotein E genotype using a heteroduplex generator
J. Lipid Res., December 1, 1999; 40(12): 2340 - 2345.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
R. W. Mahley, Y. Huang, and S. C. Rall , Jr.
Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes
J. Lipid Res., November 1, 1999; 40(11): 1933 - 1949.
[Abstract] [Full Text]

Home page
 J. Lipid Res.Home page
W. März, M. M. Hoffmann, H. Scharnagl, E. Fisher, M. Chen, M. Nauck, G. Feussner, and H. Wieland
Apolipoprotein E2 (Arg136 -> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia
J. Lipid Res., March 1, 1998; 39(3): 658 - 669.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1994 by The Endocrine Society